Physician profile
Henry Silvera
NPI 1265715684
$5,051.04
in general payments reported to CMS, 2019-2025
25 companies · $767 in 2025
The $767 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $591 · 2023: $1,289 · 2024: $842 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,037.56 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $711.88 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $576.11 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $560.19 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $538.93 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $272.81 | 2021-2022 | |
| Esperion Therapeutics, INC. | $239.72 | 2021 | |
| Novo Nordisk INC | $224.92 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $156.34 | 2021-2024 | |
| Exact Sciences Corporation | $135.73 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $124.81 | 2023 | Veozah |
| Amarin Pharma, INC. | $117.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.49 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $40.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.35 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $36.20 | 2022-2023 | Quviviq |
| Abbvie INC. | $32.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.14 | 2021 | |
| Exeltis, USA INC. | $21.10 | 2024 | Slynd |
| Allergan, INC. | $20.06 | 2021 | |
| Abbott Laboratories | $17.68 | 2022 | |
| Phadia US INC. | $17.36 | 2022 | |
| Radius Health, INC. | $17.00 | 2021 | |
| Currax Pharmaceuticals LLC | $16.86 | 2021 | |
| Dexcom, INC. | $16.73 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Silvera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.